874 results match your criteria: "Prurigo Nodularis"
Efficacy of dupilumab in chronic prurigo: A multicentre retrospective study.
Ann Dermatol Venereol
December 2024
Department of Dermatology, University Hospital of Nancy, France. Electronic address:
Association of sleep disturbance and itch intensity with quality of life impairment and disease severity in prurigo nodularis.
Br J Dermatol
December 2024
Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD, USA.
The evaluation of Congo red staining combined with fluorescence microscopy in the diagnosis of primary cutaneous amyloidosis.
J Dermatol
December 2024
Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.
Primary cutaneous amyloidosis (PCA) is a chronic pruritic skin disease. The apple-green birefringence of Congo red-stained amyloid under a polarized light microscope (CR-PLM) remains the gold standard in the diagnosis of PCA. However, there are some limitations to this approach.
View Article and Find Full Text PDFElevated C-reactive protein levels and cardiovascular risk in prurigo nodularis patients with sleep disturbance: a multi-center cohort study.
Arch Dermatol Res
December 2024
Department of Dermatology, University of Maryland School of Medicine, 419 West Redwood Street, Baltimore, MD, 21201, USA.
Patients with prurigo nodularis (PN) present with pruritus which may lead to sleep disturbances and systemic comorbidities. The objective of our study was to determine the risk of sleep disorders in PN and its association with systemic inflammation and adverse cardiovascular outcomes. We conducted a retrospective population-level cohort using a global health records database to analyze the development of sleep disorders, C-reactive protein (CRP) levels, and risk of cardiovascular disease and mortality in PN compared to controls.
View Article and Find Full Text PDFA Comprehensive Bibliometric Analysis of Prurigo Nodularis Literature (1951-2024): Key Contributors, Trends, and Thematic Evolution.
Clin Dermatol
November 2024
Institute of Chemical Sciences, University of Peshawar, Peshawar, 25120, Khyber Pakhtunkhwa, Pakistan. Electronic address:
This study provides a comprehensive bibliometric analysis of Prurigo Nodularis (PN) literature, identifying influential studies, key contributors, and emerging trends to understand the evolution of research and guide future investigations. A total of 499 papers published between 1951 and October 2024, containing the term Prurigo Nodularis in their abstracts, were analyzed. Keyword analysis was conducted to determine the main themes across these publications.
View Article and Find Full Text PDFEfficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.
JAMA Dermatol
November 2024
Department of Dermatology, University of Maryland School of Medicine, Baltimore.
Article Synopsis
Incidence and prevalence of prurigo nodularis and associated comorbidities in Denmark from 1995 to 2021.
Clin Exp Dermatol
November 2024
Medical Affairs, Sanofi A/S, Denmark.
Introduction: Prurigo nodularis (PN) is a chronic skin condition characterized by intense itching from nodular skin lesions. Despite its impact on patients' quality of life, limited data exist on its epidemiology.
Methods: A national register-based study in Denmark was conducted, utilizing data from Danish national health registers to determine the incidence and prevalence of PN diagnosed in hospitals from 1995 to 2021 and to explore the occurrence of comorbidities.
Greater Auricular Trophic Syndrome Following Parotidectomy.
WMJ
November 2024
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Article Synopsis
- - Trigeminal trophic syndrome leads to self-inflicted skin lesions due to nerve damage, while greater auricular trophic syndrome can develop after nerve sacrifice during parotid surgery.
- - A 59-year-old woman experienced ear ulceration five months post-parotidectomy, diagnosed with greater auricular trophic syndrome and treated effectively with topical clobetasol and behavioral changes.
- - Unlike other reported cases that involved mental health issues, this case involved a patient without prior psychiatric disorders, demonstrating successful treatment focusing on physical symptoms rather than psychological factors.
Efficacy and safety of narrowband ultraviolet B phototherapy for prurigo nodularis: a tertiary center experience.
An Bras Dermatol
October 2024
Department of Dermatology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
Article Synopsis
- Prurigo nodularis is a chronic skin condition that leads to intense itching, and narrowband-UVB (NB-UVB) phototherapy is a potential treatment, especially for patients with other health issues.
- In a study involving 30 patients, NB-UVB therapy resulted in complete response (80%) or partial response (20%) to treatment, with better outcomes for those with diffuse and central lesions.
- The study highlights the effectiveness and safety of NB-UVB for treating prurigo nodularis, but acknowledges its limitations, such as being conducted at a single center and having a retrospective design.
Is seborrhoeic dermatitis of infancy and childhood related to maternal history of seborrhoeic dermatitis? A large population-based cohort study from the UK.
Br J Dermatol
August 2024
Department of Dermatology, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, USA.
Article Synopsis
- The study explores the complex causes of seborrhoeic dermatitis (SebD), involving skin microbes, immunity, and genetics, noting two types: infantile and later-onset SebD.
- Researchers analyzed over a million children from a UK medical database to see if a mother's history of SebD affects the risk of their children developing either form of the condition.
- Findings indicate that maternal SebD is linked to a higher risk of children developing both ISebD and childhood-onset SebD, but children with ISebD are not likely to develop the later form.
Efficacy and safety of dupilumab in patients with prurigo nodularis.
Arch Dermatol Res
October 2024
Department of Allergy, The First Hospital of Hohhot, Hohhot, 010030, China.
Paradoxical psoriasis after dupilumab treatment of prurigo nodularis treated with adalimumab.
JAAD Case Rep
October 2024
Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
An Update on Prurigo Nodularis in Skin of Color.
J Clin Aesthet Dermatol
January 2024
Ms. Sangha is a senior medical science liaison for Incyte Corporation in Wilmington, Delaware. Prior to that, she spent over a decade as a dermatology PA specializing in general, surgical, and cosmetic dermatology. She is a fellow of the American Academy of Physician Assistants in Alexandria, Virginia. She is also a Past President of the Society of Dermatology Physician Assistants.
Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study.
Allergy Asthma Immunol Res
September 2024
Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea.
Article Synopsis
- Prurigo nodularis (PN) is a chronic skin condition characterized by severe itching that often does not respond well to standard treatments.
- A study evaluated the effectiveness of upadacitinib, a medication taken daily for 24 weeks, in 10 patients who had not improved with previous treatments, specifically cyclosporine.
- Results showed significant reductions in itching and overall skin condition severity, with no severe side effects, suggesting that upadacitinib is a promising option for managing refractory PN.
Itch and Insomnia in Patients With Prurigo Nodularis and Other Dermatologic Conditions.
J Cutan Med Surg
October 2024
Division of Dermatology, McMaster University, Hamilton, ON, Canada.
Association between atopic dermatitis and prurigo nodularis: a systematic review and meta-analysis.
Int J Dermatol
September 2024
Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Article Synopsis
- Atopic dermatitis (AD) and prurigo nodularis (PN) are chronic skin conditions characterized by intense itching and eczema-like lesions, which significantly impact patients' quality of life.
- Recent research has shown a strong connection between AD and PN, with a meta-analysis revealing that individuals with PN have a much higher risk of developing AD (odds ratio of 16.85) and a notable prevalence of PN among those with AD (2.00%).
- These findings suggest a complex relationship between the two conditions that warrants further research to better understand their interactions and improve treatment approaches.
CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity.
J Allergy Clin Immunol
September 2024
Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY; Department of Dermatology, University of Rochester Medical Center, Rochester, NY. Electronic address:
Article Synopsis
- Atopic dermatitis (AD) is an inflammatory skin condition linked to varying levels of Staphylococcus aureus, which affects disease severity and responds to treatments like dupilumab.
- This study aimed to identify host genes related to S aureus levels and AD severity using data from a clinical trial involving 71 adults with moderate-to-severe AD.
- The findings revealed a positive correlation between CERS1 expression (a gene associated with skin lipids) and both S aureus abundance and AD severity, suggesting CERS1 could serve as a biomarker for skin barrier dysfunction, with changes observable after dupilumab treatment.
Trends in Dermatological Diagnoses During Covid-19 Pandemic in Nigeria: A Retrospective Study.
West Afr J Med
June 2024
Department of Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria Phone number: 08037756969; Email:
Article Synopsis
- The study investigates the impact of the COVID-19 pandemic on dermatology outpatient services in Sub-Saharan Africa, particularly at a hospital in Nigeria.
- It compares diagnostic patterns of dermatological conditions before and during the pandemic, revealing a decrease in certain conditions and an increase in others.
- The findings suggest that while weekly clinic visits remained stable, the types of skin disorders diagnosed shifted, highlighting the need for better preparedness for future health crises.
Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis.
Life (Basel)
September 2024
Department of Otorhinolaryngology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Article Synopsis
- Abrocitinib is a JAK1 inhibitor mainly approved for treating moderate-to-severe atopic dermatitis in those 12 and older, but this review explores its off-label uses.
- Researchers found 37 studies using Abrocitinib for conditions beyond atopic dermatitis, with common cases including vitiligo, prurigo nodularis, and hand eczema, each having 12 reported instances.
- All but one of the 103 patients studied experienced favorable outcomes with Abrocitinib, highlighting its potential for treating multiple skin conditions.
Treating Chronic Pruritus: Are We at the Threshold of a Breakthrough?
Skin (Milwood)
July 2024
Department of Dermatology, University of California at San Francisco, San Francisco, California, USA.
Chronic pruritis, characterized by persistent itchiness lasting more than six weeks, affects up to 15% of the population, significantly impairing quality of life. Despite its prevalence and impact, there is an absence of FDA-approved medications specifically for the treatment of chronic pruritus, highlighting a significant unmet need in dermatology. Advancements in dermatologic medications, however, including the development of biologics and Janus kinase (JAK) inhibitors, signal potential breakthroughs in pruritus management through a radically different mechanism of action that focuses on their effect on the nervous system.
View Article and Find Full Text PDFTime is the answer: Dupilumab effectiveness in prurigo nodularis patients.
J Eur Acad Dermatol Venereol
October 2024
Dermatology Department, Kings College Hospital Foundation Trust, London, UK.
Prurigo Nodularis Mechanisms and Current Management Options.
Cutis
August 2024
Taylor A. Brown is from the Washington State University Elson S. Floyd College of Medicine, Spokane. Dr. Khachemoune is from the Department of Dermatology, Brooklyn VA Medical Center, New York, and SUNY Downstate Dermatology Service, Brooklyn.
Article Synopsis
- Prurigo nodularis (PN) is a skin condition characterized by itchy lesions that can severely affect a person's quality of life.
- Its symptoms can resemble those of other skin disorders, making diagnosis challenging and leading to potential misidentification.
- The treatment landscape for moderate to severe PN has improved with the FDA-approved medication dupilumab, and the review discusses PN's underlying mechanisms, tissue characteristics, and treatment options.
Global Burden of Atopic Dermatitis: Examining Disease Prevalence Across Pediatric and Adult Populations World-Wide.
Dermatol Clin
October 2024
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 7th Floor South Tower, Philadelphia, PA 19104, USA. Electronic address:
Article Synopsis
- Atopic Dermatitis (AD) is a widespread itchy skin condition that imposes significant health burdens and high treatment costs.
- * The condition affects people of all ages, but most research has focused on children, with fewer studies on adults.
- * Understanding AD prevalence across different populations is essential for enhancing the quality of life for affected patients and their caregivers.
Abrocitinib for prurigo nodularis: Clinical efficacy and safety profile.
J Eur Acad Dermatol Venereol
September 2024
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, China.
[Translated article] Consensus on the Diagnostic Algorithm for Chronic Nodular Prurigo.
Actas Dermosifiliogr
December 2024
Hospital General Universitario Dr. Balmis, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
Article Synopsis
- Chronic nodular prurigo (CNP) is a long-lasting skin condition causing intense itching and the formation of nodular lesions.
- The study aimed to develop a consensus among experts for a clinical diagnosis of CNP through literature review and an organized diagnostic algorithm.
- The algorithm includes three main steps: identifying potential CNP cases, diagnosing and assessing the condition, and categorizing CNP based on underlying factors, promoting a multidisciplinary treatment approach.